The challenge of analyzing beta-blocker drugs in sludge and wastewater

Marco Scheurer1, Maria Ramil, Chris D Metcalfe

  • 1Bundesanstalt für Gewässerkunde (BfG), 56068 Koblenz, Germany.

Related Concept Videos

Biological Treatment of Effluent and Waste Water01:30

Biological Treatment of Effluent and Waste Water

Biological wastewater treatment relies on the metabolic activity of microorganisms to remove pollutants from sewage. In modern treatment systems, this process is organized into sequential stages that progressively reduce solid material, dissolved organic matter, and microbial contamination. Each stage plays a distinct role in improving water quality and preparing the effluent for safe discharge or reuse.Primary and Secondary TreatmentPrimary treatment is a physical process that removes large...
Microbial Wastewater Treatment01:30

Microbial Wastewater Treatment

Microbial communities in aquatic ecosystems play a key role in the natural breakdown of contaminants introduced through domestic and industrial effluents. Acting as biological catalysts, these microbes change and mineralize a wide range of organic and inorganic pollutants under different redox conditions.In oxygen-rich surface waters, aerobic heterotrophs lead organic matter breakdown, using oxygen as the terminal electron acceptor to efficiently oxidize substrates to carbon dioxide and water.
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...